Studies have indicated that miR-133b can regulate oncogenic transcripts of gastric, esophageal, or breast cancer by targeting Fascin Actin-Bundling Protein 1(FSCIN1)/Sp1 [24,25], the epidermal growth factor receptor (EGFR) [26] and SRY-Box Transcription Factor 9 (SOX9) [27], respectively. Here, EGFR is linked to breast cancer.